Integrating_Incretin-Based_Therapy

Integrating_Incretin-Based_Therapy

ID:40719223

大小:337.58 KB

页数:8页

时间:2019-08-06

Integrating_Incretin-Based_Therapy_第1页
Integrating_Incretin-Based_Therapy_第2页
Integrating_Incretin-Based_Therapy_第3页
Integrating_Incretin-Based_Therapy_第4页
Integrating_Incretin-Based_Therapy_第5页
资源描述:

《Integrating_Incretin-Based_Therapy》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库

1、ThissupplementissponsoredbyPrimaryCareEducationSUPPLEMENTTOConsortiumandthePrimaryCareMetabolicGroupandwasFREEsupportedbyaneducationalgrantbyAmylinPharmaceuticals,1.0CMELLC.IthasbeeneditedandpeerreviewedbyTheJournalofCREDITFamilyPractice.www.pcmg-us.o

2、rgAvailableatjfponline.comVOL62,NO6/JUNE2013IntegratingIncretin-BasedTherapyintoType2DiabetesManagementLEARNINGOBJECTIVESStephenA.Brunton,MD,FAAFP1.ExplaintheconceptoftheincretineffectAdjunctClinicalProfessor,DepartmentofFamilyMedicineanddescribedefec

3、tsinincretinsecretionUniversityofNorthCarolina,ChapelHill,NorthCarolinaandincretinactionthatoccurintype2diabetesmellitus(T2DM)2.Provideanoverviewoftherationaleandnsulinresistanceandpancreaticb-celldysfunctionarewell-roleofincretin-basedtherapyasde-est

4、ablishedasthetwocorepathophysiologicdefectsinpatientswithscribedincurrentpracticeguidelinesforItype2diabetesmellitus(T2DM).In2009,DeFronzo1proposedthat6themanagementofpatientswithT2DMotherdefectsalsocontributetoglucoseintoleranceinT2DM.Amongthis3.Comp

5、aretheefficacy,safety,andtoler-“ominousoctet”ofdefects,theroleoftheincretinhormonesinthegastro-abilityoftheincretin-basedtherapiescur-rentlyavailableintestinalsystemhasbeenincreasinglyrecognized.Knownastheincretin4.Describestrategiestooptimizeincretin

6、-effect,thisphenomenonmayberesponsibleforupto70%ofinsulinsecre-basedtherapytioninresponsetooralglucoseoramealinhealthyindividuals.2Ofthein-cretinhormones,glucagon-likepeptide-1(GLP-1)isparticularlyimportantTARGETAUDIENCEPrimarycarephysiciansandclinici

7、ansaspostprandiallevelsofGLP-1aredecreasedinpatientswithimpairedglu-cosetoleranceorT2DM.3SinceGLP-1affectsglucosehomeostasisbyre-withaninterestindiabetestreatmentandmanagementducingthefastingplasmaglucose(FPG)andpostprandialplasmaglucose(PPG)levels,4p

8、harmacologicagentsthatraisetheleveloractivityofGLP-1SPONSORDISCLOSURESTATEMENThavebeendeveloped.Thisarticlecomparesthe7agentscurrentlyavailableDrStephenBruntondisclosesthatheisontheadvisoryboardsforAbbott,Boehringer-thatactontheincretinsystem,

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。
相关文章
更多
相关标签